Drugs / LUTADENOVEC AUTOGENE
LUTADENOVEC AUTOGENE
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03639714 | Feb 2019 → Nov 2022 | colorectal cancer, gastroesophageal adenocarcinoma, non-small cell lung carcinoma, urothelial carcinoma | Gritstone bio, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05456165 | May → Sep 2022 | colonic neoplasm | Gritstone bio, Inc. | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05141721 | Feb 2022 → Mar 2027 expected | colorectal neoplasm | Seattle Project Corporation | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUTADENOVEC AUTOGENE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068263 ↗ |
| Known as | GRT-C901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05141721 ↗ |
| Known as | Lutadenovec autogen | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068263 ↗ |
| Modality | Vaccine | “individualized neoantigen cancer vaccine” NCT05456165 ↗ |
| Route | Intramuscular | “administered via intramuscular (IM) injections” NCT05456165 ↗ |